**Core Concept**
Aldose reductase inhibitors are a class of drugs that target the enzyme aldose reductase, which is involved in the polyol pathway of glucose metabolism. This pathway is activated in diabetic patients, leading to the accumulation of sorbitol and fructose in cells, causing oxidative stress and tissue damage.

**Why the Correct Answer is Right**
Aldose reductase inhibitors, such as epalrestat and ranirestat, work by inhibiting the activity of aldose reductase, thereby reducing the conversion of glucose to sorbitol. This action helps to alleviate the oxidative stress and tissue damage associated with diabetic neuropathy, a common complication of diabetes. By reducing the accumulation of sorbitol, these drugs also help to prevent the activation of protein kinase C, a key enzyme involved in the development of diabetic complications.

**Why Each Wrong Option is Incorrect**
**Option A:** Aldose reductase inhibitors are not primarily used to treat hypertension or cardiovascular disease.
**Option B:** While these drugs may have some effects on glucose metabolism, they are not primarily used to treat type 2 diabetes mellitus.
**Option C:** Aldose reductase inhibitors are not typically used to treat conditions such as gout or hyperuricemia.

**Clinical Pearl / High-Yield Fact**
Aldose reductase inhibitors are a useful adjunctive therapy in the management of diabetic neuropathy, particularly in patients with advanced disease or those who are resistant to other treatments.

**Correct Answer: D. Diabetic neuropathy.